JP2024527380A5 - - Google Patents

Info

Publication number
JP2024527380A5
JP2024527380A5 JP2024501166A JP2024501166A JP2024527380A5 JP 2024527380 A5 JP2024527380 A5 JP 2024527380A5 JP 2024501166 A JP2024501166 A JP 2024501166A JP 2024501166 A JP2024501166 A JP 2024501166A JP 2024527380 A5 JP2024527380 A5 JP 2024527380A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
rnai
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/056278 external-priority patent/WO2023281434A1/en
Publication of JP2024527380A publication Critical patent/JP2024527380A/ja
Publication of JP2024527380A5 publication Critical patent/JP2024527380A5/ja
Pending legal-status Critical Current

Links

JP2024501166A 2021-07-09 2022-07-07 腎機能障害を有する個体へのオリゴヌクレオチドの使用 Pending JP2024527380A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220400P 2021-07-09 2021-07-09
US63/220,400 2021-07-09
PCT/IB2022/056278 WO2023281434A1 (en) 2021-07-09 2022-07-07 Use of oligonucleotides for individuals with renal impairment

Publications (2)

Publication Number Publication Date
JP2024527380A JP2024527380A (ja) 2024-07-24
JP2024527380A5 true JP2024527380A5 (cg-RX-API-DMAC7.html) 2025-07-08

Family

ID=82703082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501166A Pending JP2024527380A (ja) 2021-07-09 2022-07-07 腎機能障害を有する個体へのオリゴヌクレオチドの使用

Country Status (7)

Country Link
US (1) US20240336921A1 (cg-RX-API-DMAC7.html)
EP (1) EP4367241A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527380A (cg-RX-API-DMAC7.html)
CN (1) CN117616121A (cg-RX-API-DMAC7.html)
CA (1) CA3224600A1 (cg-RX-API-DMAC7.html)
TW (1) TW202323525A (cg-RX-API-DMAC7.html)
WO (1) WO2023281434A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242321A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
EA008940B1 (ru) 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
JP5775581B2 (ja) 2010-08-20 2015-09-09 レプリコール インコーポレーティッド オリゴヌクレオチドキレート錯体
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
KR20170029577A (ko) 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
JOP20190015A1 (ar) * 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US20200147124A1 (en) 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
TWI872048B (zh) * 2019-02-07 2025-02-11 美商艾羅海德製藥公司 用於B型肝炎病毒感染之RNAi劑
TW202103698A (zh) * 2019-04-18 2021-02-01 美商健生醫藥公司 用於治療b型肝炎病毒感染之組合療法
US20200332297A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection

Similar Documents

Publication Publication Date Title
TWI761311B (zh) 拮抗b型肝炎病毒之組成物和藥劑及彼等之用途
TWI872048B (zh) 用於B型肝炎病毒感染之RNAi劑
TWI702045B (zh) 治療甲狀腺素運載蛋白(ttr)調節之澱粉樣變性的方法
FI3837366T3 (fi) Hepatiitti b -viruksen (hbv) dsrna-ainekoostumuksia ja niiden käyttömenetelmiä
JP2024153797A5 (cg-RX-API-DMAC7.html)
JP6922030B2 (ja) B型肝炎およびd型肝炎ウイルス感染の治療のための方法
US20240052350A1 (en) Oligonucleotide and use thereof against hepatitis b virus and hepatitis d virus
JP2022532211A5 (cg-RX-API-DMAC7.html)
JP2022515778A5 (cg-RX-API-DMAC7.html)
US11685921B2 (en) Molecules and agents for treating hepatitis B virus
JP2025096283A5 (cg-RX-API-DMAC7.html)
JP2024544532A5 (cg-RX-API-DMAC7.html)
US20240425859A1 (en) Pharmaceutical combinations for treatment of hbv
WO2010008474A4 (en) Methods for treating multiple sclerosis using antisense oligonucleotides
CN114057816B (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
JP7376679B2 (ja) Hbv感染の処置のためのeyp001とifnの相乗効果
JP2024528659A5 (cg-RX-API-DMAC7.html)
CN121003688A (zh) 一种dsRNA与干扰素的联合治疗
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
HK40092095A (en) Pharmaceutical combined formulation for prevention or treatment of chronic hepatitis b, use thereof and combined formulation kit containing the same
HK40092095B (en) Pharmaceutical combined formulation for prevention or treatment of chronic hepatitis b, use thereof and combined formulation kit containing the same
TH2101000823A (th) องค์ประกอบสาร dsRNA ไวรัสตับอักเสบ B (HBV) และวิธีการใช้ขององค์ประกอบนั้น